Navigation Links
Athera Signs Distribution Agreement in Scandinavia
Date:8/27/2010

Athera Signs Distribution Agreement in Scandinavia -- STOCKHOLM, August 27, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Contracts, New Products & Services Click to view news release full screen  

Athera Signs Distribution Agreement in Scandinavia

 

STOCKHOLM, August 27, 2010 /PRNewswire/ -- Athera Biotechnologies and Electra-Box Diagnostica, announced today that they have signed an agreement for distribution of "CVDefine" kit. CVDefine measures a new biomarker in blood, a specific anti-body, that has been linked to increased risk for cardiovascular disease. Athera Biotechnologies is part of the Karolinska Development portfolio.

Carina Schmidt, VD i Athera:

"This is an important step in the broader commercialization of CVDefine. Together with Electra-Box we will now be able to expand our contacs with leading clinial scientist in the cardiovascular field and increase the exposure of our trademark. We look forward to be able to work with the experienced Electra-Box team."

Peter Blom, responsible for clinical chemistry in Electra-Box Diagnostica: "We are very excited about the opportunities this agreement present. This will allow us to offer a new CVD biomarker to customers in Scandinavia. Since CVDefine(R) may add important and independent information in cardiovascular risk assessment; we believe there is a lot of interest from scientist in the field to generate further clinical research data".

High levels of IgM antibodies against phosphorylcholine (anti-PC) have been shown to be cardio-protective. Low levels of anti-PC are known to be involved in atherosclerosis development and increased risk for acute cardiovascular events, like stroke and myocardial infarction. Athera is investigating the possibilities to develop new immunological therapies to prevent secondary cardiovascular events and to identify the patients who benefit most from this treatment with CVDefine, and consequently contribute to better care after acute heart disease.

To The Editors

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is part of the Karolinska Development AB (publ) portfolio. http://www.athera.se

About CVDefine

CVDefine(R) is a diagnostic test measuring IgM anti-bodies against phosphorylcholine (anti-PC). Low levels of anti-PC indicate a risk for future development of cardiovascular disease (CVD). CVDefine(R) is an ELISA kit for early detection of increased cardiovascular risk due to atherosclerosis and vascular inflammation.

About Karolinska Development (publ)

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation Pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio contains a total of 21 potential first-in-class products. http://www.karolinskadevelopment.com

About Electra-Box Diagnostica AB:

Electra-Box Diagnostica is a distribution company for products to research and clinical laboratories in Sweden, Denmark, Norway, Finland and Baltic countries. http://www.electrabox.com

For additional information, please contact: Carina Schmidt, CEO Athera Biotechnologies AB Phone: +4670-552-5115 E-mailt: c.schmidt@athera.se
'/>"/>

SOURCE Athera Biotechnologies AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Athera Receives Allowance of Two Key Patents
2. Athera Signs Agreements With German and UK Distributors for New Cardiovascular Biomarker
3. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
4. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
5. Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market
6. Microbix Signs $2 Million Partnership Agreement For its Livestock Semen Sexing Technology (LumiSort(TM))
7. Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract
8. Therapure Biopharma Inc. Signs Biomanufacturing Contract with Diamedica Incorporated
9. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
10. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
11. Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Information Management ... Web product. The upgrade represents a completely new technical foundation and is so ... offer a responsive design interface, significantly increased speed for search results, a streamlined layout ...
(Date:2/8/2016)... Feb. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has ... resource–user-centric, story-driven, knowledge-based and mobile-friendly. Visit the new ... ... ... "The goal was to reimagine ...
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/4/2016)... - New FDA action date of July 22, ... July 22, 2016   --> - ...   - Lifitegrast has the potential to be the ... signs and symptoms of dry eye disease in adults ... product approved in the U.S. in the past decade indicated for the treatment of ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
Breaking Biology News(10 mins):